|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, the results of the present study indicated that CLDN12 promoted cell proliferation and migration through the PI3K/Akt signaling pathway in osteosarcoma cells, suggesting that CLDN12 may be a potential agent in the treatment of patients with osteosarcoma.
|
31807064 |
2019 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
We discovered that TIIA inhibited osteosarcoma cell survival through class I PI3K and Akt signaling pathways.
|
30258193 |
2018 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we review these cancer signaling pathways, including Notch, Wnt, Hedgehog, phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT, and JAK/STAT, and their specific role in osteosarcoma.
|
28061797 |
2017 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of FER1L4 promotes the apoptosis and suppresses epithelial-mesenchymal transition and stemness markers via activating PI3K/AKT signaling pathway in osteosarcoma cells.
|
31000382 |
2019 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The activation of PI3K/Akt and the overexpression of fatty acid synthase (FASN) are frequently observed in human osteosarcoma (OS).
|
24366211 |
2014 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
The short interference RNA (siRNA) targeting NMUR2 relieves nociception in a bone cancer pain model of rat through PKC-ERK and PI3K-AKT pathways.
|
30914203 |
2019 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of PI3K/Akt/mTORC1 signaling may be effective in osteosarcoma, but further studies are required to determine whether this pathway is active in a substantial subgroup of this heterogeneous tumor.
|
24447333 |
2014 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data revealed for the first time that MALAT1 increases stem cell-like properties by up-regulating RET via sponging miR-129-5p, and thus activates the PI3K-Akt signaling pathway and provides potential therapeutic targets for osteosarcoma treatment.
|
30481748 |
2018 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken together, XBP1 is up-regulated and has a pro-tumor effect in OS with activation of PI3K/mTOR signaling.
|
26633383 |
2015 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, the results of the present study indicate that the expression of miRNA-21, PI3K and AKT is increased in the osteosarcoma cell line MG-63, which results in reduced expression of PTEN and increased expression of proteins in the PI3K/AKT signaling pathway, and thus increases the aggressiveness of osteosarcoma cells.
|
29434694 |
2018 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data suggest that upregulation of pro-inflammatory cytokine signal in the periaqueductal gray of cancer rats amplifies PI3K-mTOR signal in this brain region and alters the descending pathways in regulating pain transmission, and this thereby contributes to the development of bone cancer-induced pain.
|
30717619 |
2019 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data first reported that DBH-AS1 may act as an oncogenic lncRNA by modulating the PI3K/Akt pathway in osteosarcoma, which may serve as a candidate prognostic biomarker and target for new therapies in osteosarcoma.
|
30840262 |
2019 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study investigated the role of miR-155 in regulating osteosarcoma cell autophagy, chemosensitivity to Adriamycin (ADM), and PTEN-PI3K/AKT/mTOR signaling pathway.
|
29412697 |
2018 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Osteosarcoma cell lines are responsive to pharmacologic and genetic inhibition of the PI3K/mTOR pathway both in vitro and in vivo.
|
25512523 |
2014 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that hBMSC-MVs promoted U2OS cell proliferation and migration under hypoxia in vitro, and that was partially associated with the PI3K/AKT and HIF-1α pathways.
|
30506278 |
2019 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The overexpression of IRX2 promoted the activation of PI3K/Akt and increased the proliferation and invasiveness of the OS cell lines as shown by CCK8 and invasion assays.
|
26062523 |
2015 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, we further found that those effects on osteosarcoma by NRSN2 are associated with the dysregulated PI3K/AKT/mTOR signaling and Wnt/β-catenin signaling.
|
28401012 |
2017 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
We determined that AREG increases the expression of intercellular adhesion molecule-1 (ICAM-1) through PI3K/Akt signaling pathway via its interaction with the epidermal growth factor receptor, thus resulting in the enhanced cell migration of osteosarcoma.
|
26503469 |
2015 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Celecoxib enhances anticancer effect of cisplatin and induces anoikis in osteosarcoma via PI3K/Akt pathway.
|
28053596 |
2017 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Although IP6 exposures had modest to minimal effects on cell proliferation, we observed reduced cellular glycolysis, down-regulation of PI3K/Akt signaling and suppression of OS metastatic progression.
|
28404949 |
2017 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, the current study reveals that aclidinium bromide might inhibit osteosarcoma cell growth by regulating the PI3K/AKT signaling pathway, which suggests aclidinium bromide is a potential chemotherapeutic agent for osteosarcoma.
|
30657552 |
2019 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on the above results, we conclude that PTEN/PI3K/Akt signaling is involved in the inhibitory effect on human OS 143B cell proliferation by EVO.
|
26135006 |
2015 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Western blot analyses revealed that circ-0001785 regulated the PI3K/Akt signaling and Bcl-2 family pathway in osteosarcoma.
|
31116090 |
2019 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
BRCA1-Associated Protein-1 Suppresses Osteosarcoma Cell Proliferation and Migration Through Regulation PI3K/Akt Pathway.
|
28256910 |
2017 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we have analyzed the therapeutic potential of the pan-PI3K inhibitor NVP-BKM120, which has recently entered clinical Phase II for treatment of PI3K-dependent cancers on three OS cell lines.
|
30536897 |
2019 |